Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
03:50pm, Friday, 21'st Jun 2024
Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials.
In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of
Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
03:45pm, Friday, 21'st Jun 2024
Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early
Three-Stock Lunch: Nvidia, Eli Lilly & Chipotle
03:20pm, Friday, 21'st Jun 2024
David Bahnsen, chief investment officer at the Bahnsen Group, joins 'Power Lunch' to discuss stock plays for three stocks, including Nvidia, Eli Lilly, and Chipotle.
3 Biotech Stocks to Buy Now: June 2024
02:00pm, Friday, 21'st Jun 2024
Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies s
Hype Busters: 3 Overvalued Stocks Ready for a Reality Check
06:22am, Friday, 21'st Jun 2024
Overvalued stocks are prevalent in today's market. Based on the historical ratio of total market cap over GDP (currently at 193.4%), the Buffett Indicator suggests that the U.S. stock market is signif
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
06:50pm, Thursday, 20'th Jun 2024
The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.
Eli Lilly Has a New Drug That Could Push the Stock Higher
02:25pm, Thursday, 20'th Jun 2024
Lilly's Alzheimer's disease drug donanemab could receive FDA approval by year-end. Donanemab would likely be covered by Medicare if approved.
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024
11:58am, Thursday, 20'th Jun 2024
Investors searching for stocks that will grow their portfolio and provide a strong return on capital should pay attention to analyst ratings, particularly the ones placed on strong buy growth stocks.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
10:06am, Thursday, 20'th Jun 2024
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
08:30am, Thursday, 20'th Jun 2024
Eli Lilly's stock is expensive and is trading at around all-time highs. That's thanks to its promising weight-loss and diabetes drugs, Zepbound and Mounjaro.
Eli Lilly's Stock Surge Driven by GLP-1 Demand
07:04am, Thursday, 20'th Jun 2024
Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have
Lilly files additional lawsuits over US sales of counterfeit Mounjaro
06:33am, Thursday, 20'th Jun 2024
U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in it
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
02:00pm, Wednesday, 19'th Jun 2024
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
07:15am, Wednesday, 19'th Jun 2024
The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that pos
